Insights & Publications

Pharmaceuticals & Medical Products

Gail Horwood - Developing a global digital strategy
commentary

Developing a global digital strategy

October 2014—How does a global company take advantage of digital technology? Johnson & Johnson’s vice president of digital strategy, Gail Horwood, explains.more

  • includes:
    •  

Editor's choice

Pharma_launches_1536x1536_Thumbnail
article

Pharma’s first-to-market advantage

September 2014—What’s the value of bringing a drug to market first? In some cases, it may be less than you think.more

Healthcares-digital-future_1536x1536_Thumbnail
article

Healthcare’s digital future

July 2014—Insights from our international survey can help healthcare organizations plan their next moves in the journey toward full digitization.more

Donaldson_1536x1536_Thumbnail
interview

Designing for social impact: The D-Rev story

June 2014—Many companies target the world’s emerging middle-class consumers. Fewer mirror nonprofit D-Rev, which aims to improve the health and lives of people living on less than $4 a day.more

  • includes:
    •  
Pharma-launches_1536x1536_Thumbnail
article

The secret of successful drug launches

March 2014—About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.more

Pharma-mergers_1536x1536_Thumbnail
article

Why pharma megamergers work

February 2014—Unlike deals in many industries, big mergers and acquisitions among pharmaceutical companies generally have resulted in positive returns to shareholders.more

FDAapprovals_1536x1152_Thumbnail
article

What’s driving the surge in new-drug approvals?

November 2013—In 2012, new-drug approvals by the US Food and Drug Administration hit a ten-year high. Can the pharmaceutical industry make this trend last?more

HealthCareSupplyChain_1536x1152_Thumbnail
article

Strengthening health care’s supply chain: A five-step plan

September 2013—Dramatically changing the sector’s inefficient supply chain may eliminate the dangers posed by counterfeiting and medication errors.more

  • includes:
    •  
hobi13_frth_Thumbnail
article

How big data can revolutionize pharmaceutical R&D

April 2013—Pharmaceutical R&D suffers from declining success rates and a stagnant pipeline. Big data and the analytics that go with it could be a key element of the cure.more

  • includes:
    •  

About this content

The material on this page draws on the research and experience of McKinsey consultants and other sources. To learn more about our expertise, please visit the Pharmaceuticals & Medical Products Practice.